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mHealth relates to the provision of health-re-
lated services via a mobile device. It comprises 
multidimensional elements including 
provider, patient and administrative appli-
cations. Applications include consumer 
education and behaviour change, wearable 
sensors and point-of-care diagnostics, disease 
and population registries, electronic health 
records, decision support, provider tools 
(communication, workflow management, 
professional education) and healthcare 
management (human resources, financial 
monitoring, supply chain logistics).1
Although mHealth has potential to 
strengthen health systems worldwide, the 
evidence base is immature, and consequently, 
the opportunities to advance knowledge 
remain limited.2 3 Mobile devices and apps 
have become essential tools for disruptive 
change in many industries, but thus far, this 
has not happened in healthcare. Here, we 
discuss five interrelated reasons as to why 
mHealth has underdelivered and highlight 
challenges and opportunities for mHealth 
researchers.
THe myTH of THe ‘killer app’
Disruptors often rely on a ‘killer app’—a 
highly popular application that users will 
consider indispensable for their needs. At last 
count, there were nearly 260 000 health apps 
on the market,4 but most downloads are never 
opened and consistent use is extremely rare. 
Further, these apps are often disease siloed, 
focus mainly on behaviour change, gloss over 
privacy issues and are not integrated into 
any overarching healthcare structure. Such 
apps struggle to achieve large-scale adop-
tion because of their failure to address the 
needs of diverse stakeholders.5 Most apps are 
consumer facing, whereas healthcare systems 
tend to be provider facing. This important 
distinction may explain why the ‘killer app’ 
approach is not the correct mindset. The 
diversity of users and the inability to address 
their varied problems results in user fickleness 
and ready abandonment of new technologies. 
When tools are not connected to systems and 
human support, they are unlikely to be effec-
tive. Consequently, moving beyond a single 
solution focus towards a ‘health ecosystem’ 
approach is needed.6
NegleCTiNg user perspeCTives aNd 
prefereNCes
Related to the killer app mythology is the 
tendency to overengineer solutions before 
having an opportunity to fully understand 
user needs, contextual factors and the size and 
specifics of the problem that needs addressing. 
The Greentree consensus outlines nine prin-
ciples for digital development, emphasising 
frequent and in-depth user engagement in 
all phases of the development process.7 It 
stresses the importance of understanding the 
ecosystem, designing for scale and sustaina-
bility, addressing privacy, using open stand-
ards and taking a data-driven approach. It 
also emphasises the need for multidiscipli-
nary collaborations. Although researchers are 
often the subject matter experts, non-health 
specialists such as human factors engineers, 
human computer interaction specialists, 
anthropologists and ethicists can provide 
strong methodological frameworks for under-
standing user perspectives at all stages of the 
development, implementation, evaluation 
cycle.8 By not taking a user-centred approach, 
we risk overengineering solutions. The most 
promising use of mHealth to date has not 
been smartphone apps, but basic functions 
such as short messaging service or voice calls 
to address specific issues such as medication 
adherence and promoting smoking cessa-
tion.9 10
apps are NoT pills
Researchers tend to lack a good under-
standing of how developers operate. Two 
commonly used industry standards include 
Waterfall and Agile development.11 Waterfall 
is a stepwise process whereby developers iter-
atively revise their software at each stage of 
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the product development cycle based on target audience 
feedback. It may be particularly appropriate for large-
scale system development. Agile design takes an incre-
mental rather than sequential approach. Initial proto-
types are usually simple and each development effort is 
completed in short sprint cycles with increasing maturity 
at each cycle. It is particularly useful when there is not 
a clear idea what might work. Whichever approach is 
used, initial deployments are unlikely to work perfectly. 
The interim goal should be a ‘good enough’ prototype, 
known in industry as the minimum viable product.
These approaches highlight differing developer and 
researcher perspectives. The developer’s outlook is 
plastic, continually updating and refining a product to 
create novel solutions and stay ahead of the competition. 
By contrast, a researcher’s outlook is more static where 
interventions are viewed as pills—specific agents that are 
developed and tested in isolation of other factors. These 
differences in perspective are often disregarded. Under-
standing the developer’s approach can help research 
teams to get apps in front of users quickly, fail early and 
build from the lessons learnt. This approach can also 
avoid expensive ‘scope creep’ later in the development 
cycle when the app is more mature and user testing 
reveals a major redesign is needed.
rigid approaCHes To evaluaTe evolviNg TeCHNologies
While we strongly support the need for evaluations with 
randomised controlled trials (RCTs), there are several 
considerations in applying this design in mHealth. First, 
traditional RCT designs reflect ‘the static view’ described 
above—assuming an intervention is ‘fixed’ and external 
factors are standardised or adjusted for to avoid intro-
ducing a bias. This is anathema to software development 
where iteration, bug fixes and new releases as user expe-
rience grows are the norm—‘the perpetual beta’. The key 
consideration here is that we test principles rather than 
fixed apps.12 The app market is constantly evolving but 
principles remain relatively constant and generate gener-
alisable knowledge of public health interest. Second, 
RCTs are good at testing efficacy but are not so good 
at answering questions related to the implementation 
strategy.13 Incorporation of theory-informed frameworks 
for understanding factors associated with adoption 
and non-adoption are therefore essential to evaluate 
programmes and generate knowledge that can be applied 
to other settings.14 A third and unexplored area is post-
marketing surveillance mechanisms to safeguard against 
unintended consequences derived from mHealth-related 
activities.15
WHaT are THe prioriTies of THose WHo pay for mHealTH 
TeCHNologies?
Public and commercial payers of health services play a 
central role in determining whether mHealth can be 
adopted at scale. Innovation in the business model is 
just as important as the apps themselves in promoting 
disruption. Greater attention to business model specifics 
may stimulate different research questions. From a 
researcher’s perspective, the priority is to demonstrate 
clinical effectiveness. This contrasts with the payer’s 
perspective which is broader and includes factors such 
as reduced administrative burden, improved workflows, 
greater patient and provider engagement and improved 
quality of care and outcomes at lower costs.16 The macro-
economic environment is also key to driving particular 
business models. While profits may be greater in high-in-
come countries, the largest mHealth market in terms of 
user numbers will be in emerging economies. Just as the 
pharmaceutical industry tends to be segmented into low 
volume, high margin products for rich countries and high 
volume, cheaper products for poorer countries, mHealth 
markets are likely to evolve differently depending on the 
payer, provider and consumer environment. It is there-
fore important that the research community generate 
evidence on effective business models as much as effec-
tive apps.
CoNClusioN
Although some may be disillusioned by the lack of ‘block-
buster’ mHealth trials, we are optimistic that the evidence 
base for mHealth will grow substantially in coming years. 
Particular challenges remain, especially in low-income 
and middle-income country settings where literacy, 
health literacy, unavailability of smartphones and limited 
access to reliable data connectivity all pose adoption 
challenges. However, these factors are improving rapidly, 
and the opportunities for future growth are substantial. 
With increasing knowledge of what works and what the 
challenges are, we will arrive at a more nuanced under-
standing of the role of mHealth in improving health and 
healthcare.
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